首页 › 期刊 › 医学 › European Urology Focus
European Urology Focus
出版商:Elsevier · ISSN:2405-4569 · 国家/地区:NL · 类型:journal · 官网:https://www.journals.elsevier.com/european-urology-focus
研究主题:Prostate Cancer Diagnosis and Treatment · Bladder and Urothelial Cancer Treatments · Prostate Cancer Treatment and Research · Urinary Bladder and Prostate Research · Renal cell carcinoma treatment
数据覆盖:10 个公开学术数据源交叉核验(crossref、fqb、jcr、openalex、scimago、submission、wikidata、xr、cwts、jufo)。
数据来源与实体核验
期刊官网 · OpenAlex 期刊实体 · Wikidata 期刊实体
核心指标
- 影响因子(JCR 2025):6.300
- JCR 分区:Q1(UROLOGY & NEPHROLOGY)
- 中科院分区(2025):医学 2区(Top),大类排名 476/5603;小类:UROLOGY & NEPHROLOGY 泌尿学与肾脏学 2区,排名 12/126
- 新锐分区(2026):医学 2区(Top)
- SJR:1.729(Q1),2025 年,Netherlands
- CWTS 2025:SNIP 2.242 · IPP 5.263 · 自引率 2.2%
- JUFO 出版渠道等级:芬兰 2 · 挪威 1
- h-index:80
- i10 指数:1050
- 近两年篇均被引:3.77
- 载文量 2296 · 总被引 42759
- Crossref DOI 总量:2295,近期 641
逐年趋势
- 近年影响因子:2020 6 → 2021 5.95 → 2022 5.4 → 2023 4.8 → 2024 5.6
- 近年 SJR:2021 1.45(Q1) → 2022 1.55(Q1) → 2023 1.47(Q1) → 2024 1.86(Q1) → 2025 1.73(Q1)
投稿参考
- 版面费(APC)约 $3800 USD(以期刊官网为准)
- 提供 LaTeX 投稿模板(elsarticle.cls)
同学科期刊推荐
- CA-A CANCER JOURNAL FOR CLINICIANS — IF 685.2 · JCR Q1 · 中科院1区(Top)
- The Lancet — IF 109.0 · JCR Q1 · 中科院1区(Top)
- MMWR Surveillance Summaries — IF 96.9 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Clinical Oncology — IF 94.6 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Drug Discovery — IF 91.2 · JCR Q1 · 中科院1区(Top)
- New England Journal of Medicine — IF 84.5 · JCR Q1 · 中科院1区(Top)
- Signal Transduction and Targeted Therapy — IF 81.2 · JCR Q1 · 中科院1区(Top)
- Annals of Oncology — IF 80.4 · JCR Q1 · 中科院1区(Top)
常见问题
《European Urology Focus》的影响因子是多少?
根据 JCR 2025 年数据,《European Urology Focus》的最新影响因子(IF)为 6.300。
《European Urology Focus》是几区期刊?
《European Urology Focus》中科院分区(2025年版)为医学2区(Top 期刊),JCR 分区为 Q1。
《European Urology Focus》的版面费(APC)是多少?
根据 OpenAlex 收录的价目,《European Urology Focus》的文章处理费(APC)约为 $3800 美元。实际费用与豁免政策请以期刊官网为准。
本刊近期代表论文
- Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis (2025 · 被引 21)
- Five-year Follow-up of the Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods—A Noninferiority Randomised Controlled Trial of Urodynamics (2025 · 被引 7)
- Strategies to Mitigate Breast-related Adverse Events in Patients with High-risk Biochemically Recurrent Prostate Cancer Receiving Enzalutamide Monotherapy: Perspectives and Challenges (2025 · 被引 3)
- Could Use of a Flexible and Navigable Suction Ureteral Access Sheath Be a Potential Game-changer in Retrograde Intrarenal Surgery? Outcomes at 30 Days from a Large, Prospective, Multicenter, Real-world Study by the European Association of Urology Urolithiasis Section (2024 · 被引 153)
- Diagnostic Test Accuracy of Urinary DNA Methylation-based Biomarkers for the Detection of Primary and Recurrent Bladder Cancer: A Systematic Review and Meta-analysis (2024 · 被引 32)
- Volumetric Quantitative Contrast-enhanced Ultrasonography Evaluation of Complex Renal Cysts: An Adjunctive Metric to the Bosniak Classification System to Predict Malignancy (2022 · 被引 7)